Document is current

Article History

Received: 22 December 2022

Accepted: 20 September 2023

First Online: 12 December 2023

Competing interests

: K.S. received salary support from Cancer Institute NSW (Australia, grant no. CDF1004). M.A. was supported by the Horizon 2020 Framework Program for Research and Innovation of the European Commission, through the Risk-based Screening for Cervical Cancer (RISCC) Network (grant no. 847845). K.C. receives salary support from the National Health and Medical Research Council (Australia, grant no. APP1135172). K.C. is co-principal investigator and M.C. is an investigator on an investigator-initiated trial of cytology and primary HPV screening in Australia (‘COMPASS’) (ACTRN12613001207707 and ), which is conducted and funded by the Australian Centre for the Prevention of Cervical Cancer, a government-funded health promotion charity. The Australian Centre for the Prevention of Cervical Cancer has received equipment and a funding contribution for the COMPASS trial from Roche Molecular Systems and operational support from the Australian Government. K.C. is also co-principal investigator on a major implementation program, ‘Elimination of Cervical Cancer in the Western Pacific’, which receives support from the Minderoo Foundation and equipment donations from Cepheid, Inc. All declared funders had no role in the study design, in the collection, analysis and interpretation of data, in the writing of the report or in the decision to submit the manuscript for publication.